Alpha Tau Initiates Groundbreaking Trial for Pancreatic Cancer
– The successful treatment of the first patient symbolizes a key development in Alpha Tau's fight against pancreatic cancer –
– This study investigates the effectiveness of Alpha DaRT combined with standard chemotherapy for patients diagnosed with advanced pancreatic cancer –
– A staggering 87% of newly diagnosed patients are inoperable, underscoring the need for innovative treatments –
– This pilot study is a vital component of Alpha Tau’s mission to address the pressing needs of cancer patients facing significant challenges –
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the innovative force behind the unique alpha-radiation therapy known as Alpha DaRT, has just marked a significant milestone by successfully treating its first patient in a pioneering multi-center pilot study aimed at pancreatic cancer. Named the IMPACT (Intratumoral Pancreatic Alpha Combination Trial), this investigation will focus on the safety, feasibility, and efficacy of Alpha DaRT when used in conjunction with chemotherapy for those suffering from unresectable locally advanced or metastatic pancreatic adenocarcinoma.
This cancer type ranks as the third leading cause of cancer-related deaths in the United States, with approximately 66,000 new diagnoses every year. Alarmingly, nearly 87% of patients with pancreatic cancer find their conditions inoperable at the time of diagnosis, leading to poor prognoses and minimal benefits from existing treatments.
Uzi Sofer, the CEO of Alpha Tau, expressed the urgency of addressing the pressing needs in pancreatic cancer care: “Given that a vast majority of these patients are classified as inoperable at diagnosis, we are excited about the initiation of the IMPACT trial. This study enables us to explore how Alpha DaRT, with its localized alpha radiation, could potentially enhance chemotherapy and offer new hope for this challenging condition. We believe that this pilot study is pivotal for advancing Alpha DaRT into broader clinical practice for patients in dire need.”
The initial treatment was delivered at a leading cancer center in Houston by a skilled multi-disciplinary team, including the Principal Investigator, Dr. Mark D'Andrea, a Radiation Oncologist, and Dr. Isaac Raijman, a Gastroenterologist. Their collaborative efforts underscore the importance of expertise in tackling such a complex illness.
Dr. D’Andrea commented on the promising nature of Alpha DaRT: “The Alpha DaRT applicators are engineered to emit high-energy alpha particles that travel only a short distance in tissues. This characteristic is particularly advantageous for treating pancreatic tumors, which are situated close to critical structures. This new approach could facilitate better local control compared to traditional therapies.”
Furthermore, Dr. Raijman highlighted the minimally invasive aspect of the treatment: “Our methodology used real-time endoscopic ultrasound guidance to accurately place Alpha DaRT sources into the pancreatic tumor. This non-invasive technique allows us to target deeply located tumors while potentially minimizing side effects, paving the way for a fresh interventional strategy for such a devastating disease.”
Dr. Robert Den, the Chief Medical Officer of Alpha Tau, elaborated on the thoughtful design of the IMPACT study: “This trial is rooted in our robust pre-clinical research, aiming to merge Alpha DaRT with chemotherapy for advanced pancreatic cancer. We seek to collect high-quality clinical data regarding both safety and preliminary efficacy, shaping our future development directions. Our ultimate aim is to provide localized treatment options that could significantly improve patient outcomes.”
About the IMPACT Study
The IMPACT study plans to enroll up to 30 patients: 15 diagnosed with inoperable locally advanced pancreatic cancer and another 15 with metastatic disease, across various centers in the U.S., Canada, and Israel. All participants must meet specific eligibility criteria, including having newly diagnosed, histologically confirmed pancreatic adenocarcinoma and being chemotherapy-naïve or within their initial treatment cycles.
Throughout the course of the study, patients will persist with their standard chemotherapy treatment (mFOLFIRINOX), while Alpha DaRT sources will be implanted into the tumor via ultrasound-guided endoscopy. Follow-up assessments will occur for up to six months post-enrollment, focusing on patient safety and treatment response.
The primary goals of this investigation include determining the feasibility of Alpha DaRT source implantation and monitoring safety and tolerability throughout the treatment process. Secondary objectives encompass measuring local tumor response, evaluating progression-free survival, overall survival, and assessing patient-reported outcomes, particularly concerning pain management.
Alpha Tau Medical Ltd., founded in 2016, is committed to advancing the science of oncology therapeutics, with a particular focus on Alpha DaRT's potential against solid tumors. Their unique technology, initiated by pioneering researchers from Tel Aviv University, aims to improve the lives of cancer patients, and the initiation of the IMPACT trial marks a significant advancement in this mission.
As Alpha Tau continues its innovative paths in cancer treatments, the world watches with anticipation for advancements that could lead to better outcomes for patients facing dire diagnoses.
Frequently Asked Questions
What is the focus of the IMPACT trial?
The IMPACT trial investigates the use of Alpha DaRT in combination with chemotherapy for patients with unresectable pancreatic cancer.
Who is involved in the study?
A multidisciplinary team, including radiation oncologists and gastroenterologists, is conducting the study across multiple centers.
What are the expected outcomes of the study?
The primary outcomes include assessing safety, feasibility, and local tumor response to the treatment.
How does Alpha DaRT differ from conventional therapies?
Alpha DaRT targets tumors with localized alpha radiation, aiming for minimal impact on surrounding healthy tissues.
Who can participate in the trial?
Eligible participants are adults with newly diagnosed, inoperable pancreatic adenocarcinoma who meet specific criteria.
